Anatomic location of measurable uninjected lesions in talimogene laherparepvec study
| Any | Evaluablea | |
|---|---|---|
| n (%) | n (%) | |
| Any uninjected non-visceral, number of patients (%) | 49 (100) | 42 (100) |
| Any non-visceral, number of patients (%) | 48 (98.0) | 39 (92.9) |
| Head/Neck, Front, number of lesions (%) | 2 (4.1) | 1 (2.4) |
| Head/Neck, Back | 1 (2.0) | 1 (2.4) |
| Head/Neck, Right | 4 (8.2) | 4 (9.5) |
| Head/Neck, Left | 4 (8.2) | 4 (9.5) |
| Trunk, Front | 13 (26.5) | 10 (23.8) |
| Trunk, Back | 6 (12.2) | 5 (11.9) |
| Lower Limb, Right | 5 (10.2) | 5 (11.9) |
| Lower Limb, Left | 8 (16.3) | 8 (19.0) |
| Upper Limb, Right | 4 (8.2) | 3 (7.1) |
| Upper Limb, Left | 2 (4.1) | 1 (2.4) |
| Right Hand, Palm | 1 (2.0) | 1 (2.4) |
| Right Hand, Back | 1 (2.0) | 1 (2.4) |
| Groin | 2 (4.1) | 2 (4.8) |
| Lymph node, specify | 21 (42.9) | 16 (38.1) |
| Other | 16 (32.7) | 8 (19.0) |
| Any visceral, number of patients (%) | 23 (46.9) | 15 (35.7) |
| Eye, number of lesions (%) | 1 (2.0) | 0 (0.0) |
| Brain | 3 (6.1) | 0 (0.0) |
| Lung | 17 (34.7) | 12 (28.6) |
| Gastrointestinal Tract | 3 (6.1) | 1 (2.4) |
| Kidney | 3 (6.1) | 0 (0.0) |
| Adrenal | 4 (8.2) | 1 (2.4) |
| Liver | 8 (16.3) | 4 (9.5) |
| Pancreas | 3 (6.1) | 2 (4.8) |
| Spleen | 4 (8.2) | 0 (0.0) |
Denominator is the total number of patients. Patients may have multiple lesions
aEvaluable indicates at least 2 assessments with valid measurements
All patients received at least one dose of talimogene laherparepvec